A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Active:	Yes
Cancer Type:	Hematopoietic Malignancies Lymphoma Non-Hodgkin Lymphoma Unknown Primary	NCT ID:	NCT05100862
Trial Phases:	Phase III	Protocol IDs:	BGB-3111-308 (primary) NCI-2023-09690 2022-502548-12-00 CTR20232545
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	BeiGene
NCI Full Details:	http://clinicaltrials.gov/show/NCT05100862

Summary

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab
versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R)
follicular lymphoma (FL), as measured by progression-free survival as determined by an
independent review committee in accordance with the 2014 modification of the
International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron
emission tomography and computed tomography (PET/CT), and to compare the efficacy of
zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma
(MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with
CT-based Lugano 2014 Criteria.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.